3 Dividend Stocks to Buy in November That Keep Paying

Colgate-Palmolive has raised its dividend for 63 consecutive years, McDonald’s for 50 years (its latest quarterly payout rose 4% to $1.93 per share), and Target is on track for 55 consecutive annual increases in 2026, with a current quarterly payout of $1.16 and a yield around 3%. The article presents these records as evidence of management commitment despite business and share-price pressure, while emphasizing that boards can cut dividends and past increases are not guarantees.

Analysis

The investable signal is not the length of the streak; it is whether cash generation can support the payout without crowding out reinvestment or weakening the balance sheet. A board’s willingness to keep increasing a dividend can constrain flexibility precisely when competition or a turnaround requires spending. The streak therefore offers little protection against a deteriorating payout ratio, falling free cash flow, or rising funding costs.

Near term, dividend-focused demand may support these shares in a risk-off tape, but the yield is not a catalyst by itself: price declines can raise yield while worsening the underlying risk. Over 1–3 months, MCD’s key test is whether U.S. comparable-sales momentum and traffic improve; for TGT, whether the turnaround produces sustained sales and margin recovery, not just a sequential bounce. CL is the cleaner defensive exposure if household-product demand and cash conversion hold, though it still competes for investor capital with other staples, including Procter & Gamble.

Over 6–18 months, the main divergence is business execution rather than dividend history. TGT has the greatest risk that discretionary weakness or turnaround costs make dividend growth compete with operational investment. MCD’s payout confidence is also exposed to weaker restaurant traffic and franchisee economics. The contrarian point: a long record can encourage investors to treat the dividend as bond-like, potentially understating equity downside; the payout is discretionary and does not cap drawdowns.

Key Decisions for Investors

• Do not buy any of the three on streak length or headline yield alone. Before initiating, verify trailing and forward free-cash-flow coverage, payout ratio, debt maturities, and planned capital spending; these data are not provided here.
• For a defensive relative-value expression, consider overweighting CL versus TGT only if CL’s cash-flow coverage remains sound and TGT has not yet shown sustained comparable-sales and margin improvement. Reassess after company results; reverse the relative view if TGT demonstrates durable recovery without deterioration in cash generation.
• Treat MCD as a watch/hold rather than a dividend-driven add until U.S. traffic and comparable sales stabilize. A dividend increase without operating improvement would not validate the earnings trajectory.
• Thesis falsifiers: a meaningful deterioration in free-cash-flow coverage or an adverse payout outlook at any company; for TGT, continued sales or margin slippage; for MCD, persistent traffic weakness; for CL, weakening cash conversion alongside loss of pricing or volume.